Response kinetics and factors predicting survival in core-binding factor leukemia

[1]  H. Kantarjian,et al.  Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia , 2017, American journal of hematology.

[2]  D. Weisdorf,et al.  Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy , 2014, American journal of hematology.

[3]  H. Kantarjian,et al.  Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia , 2014, American journal of hematology.

[4]  Yu Wang,et al.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. , 2013, Blood.

[5]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[6]  E. Estey,et al.  Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival , 2008, Cancer.

[7]  T. Naoe,et al.  Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan , 2008, International journal of hematology.

[8]  P. Marlton,et al.  A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse , 2008, Leukemia & lymphoma.

[9]  W. Hiddemann,et al.  The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors , 2007, Leukemia.

[10]  H. Gundacker,et al.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations , 2006, British journal of haematology.

[11]  H. Hasle,et al.  Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. , 2006, Leukemia research.

[12]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Preudhomme,et al.  Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) , 2005, Leukemia.

[14]  A. Ganser,et al.  Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Hiddemann,et al.  New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. , 2003, Blood.